493,276 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Purchased by DDD Partners LLC

DDD Partners LLC acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 493,276 shares of the company’s stock, valued at approximately $5,974,000. DDD Partners LLC owned about 0.10% of Elanco Animal Health as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. Commerce Bank lifted its stake in shares of Elanco Animal Health by 2.2% during the 3rd quarter. Commerce Bank now owns 35,114 shares of the company’s stock valued at $516,000 after buying an additional 741 shares in the last quarter. MTM Investment Management LLC lifted its position in shares of Elanco Animal Health by 9.3% during the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company’s stock worth $172,000 after acquiring an additional 1,200 shares in the last quarter. Keene & Associates Inc. boosted its holdings in shares of Elanco Animal Health by 5.7% in the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock worth $337,000 after acquiring an additional 1,240 shares during the period. M&T Bank Corp grew its position in shares of Elanco Animal Health by 5.9% in the third quarter. M&T Bank Corp now owns 26,407 shares of the company’s stock valued at $388,000 after purchasing an additional 1,464 shares in the last quarter. Finally, Venturi Wealth Management LLC raised its stake in shares of Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after purchasing an additional 1,601 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $11.26 on Monday. Elanco Animal Health Incorporated has a 52-week low of $10.77 and a 52-week high of $18.80. The company has a fifty day moving average of $11.94 and a 200-day moving average of $13.15. The company has a market capitalization of $5.57 billion, a P/E ratio of 28.15, a P/E/G ratio of 2.69 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Analyst Ratings Changes

Several research analysts have commented on the company. Morgan Stanley cut their target price on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 29th. Stifel Nicolaus reduced their price objective on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Barclays increased their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. UBS Group initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price target for the company. Finally, Leerink Partners started coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Elanco Animal Health presently has an average rating of “Hold” and an average target price of $16.29.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.